Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Available × INDUSTRY × tipifarnib × Clear all

Status

Completed 9 Withdrawn 1 Terminated 1 Available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell, Peripheral 1 Lymphoma 1

Interventions

tempol 2 balstilimab 2 zolbetuximab 1 venetoclax 1 ulixertinib 1 tisagenlecleucel 1 tipifarnib 1 telisotuzumab vedotin 1 tebentafusp 1 talazoparib 1 sodium thiosulfate 1 selinexor 1 ruxolitinib 1 ribociclib 1 osunprotafib 1 nirogacestat 1 mirdametinib 1 idecabtagene vicleucel 1 gedatolisib 1 ensartinib 1 dodecyl maltoside 1 ceritinib 1 burosumab 1 brexucabtagene autoleucel 1 belantamab mafodotin 1 axicabtagene ciloleucel 1 asciminib 1 anlotinib 1 TEMPOL-H 1 Sunitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04809233 2025-06-04

Expanded Access to Tipifarnib

Kura Oncology, Inc.

Lymphoma, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡